Drug Database
Back to search

Poland· PL-100325822

Plegridy

A peginterferon beta-1a product containing peginterferonum beta-1a, registered in Poland by Biogen Netherlands B.V.. The same ATC class is registered in 14 of our 19 countries.

ATC L03AB13

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedPlegridyATCL03AB13REGISTER NO.PL-100325822PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about peginterferonum beta-1aAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Peginterferon beta-1a is registered in 14 of 19 countries.

Countries holding a registration under ATC L03AB13 (peginterferon beta-1a), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose
Search peginterferon beta-1a products by name

Peginterferon beta-1a · ATC L03AB13

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of peginterferon beta-1a costs, country by country.

Normalised to the WHO defined daily dose (8.9 mcg), the median price runs from $1.58 in Czechia to $45.18 in Switzerland — a ×29 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Peginterferon beta-1a · price per daily dose (8.9 mcg)

USD · FX 28 Sept 2026

  • CH Switzerland$45.18
  • CZ Czechia$1.58
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Peginterferonum beta-1a
Manufacturer
Biogen Netherlands B.V.
Country
Poland (PL)
ATC code
L03AB13
ATC class
Peginterferon beta-1a
Defined daily dose
8.9 mcg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    00646520441970
  • gtin
    00646520437201

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

338 interactions on record for peginterferon beta-1a.

Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check peginterferon beta-1a against other medicinesHow interaction checks work

Peginterferon beta-1a · interactions on record

338 records

  • 15 severe
  • 323 moderate

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • ZidovudineJ05AF01severe
  • ClotrimazoleA01AB18moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Peginterferon beta-1a in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All peginterferon beta-1a products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Plegridy
  • Liechtenstein · Plegridy
  • Norway · Plegridy

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/322da1ce-e668-4a0b-b4dd-fdc152d410b8
GET /v1/drugs/322da1ce-e668-4a0b-b4dd-fdc152d410b8?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań",
  "source": "urpl",
  "strength": "(63 mcg + 94 mcg)/0,5 ml",
  "packaging": "00646520441970 ¦ Rpz ¦ EU/1/14/934/001 ¦ 104005\n1 amp.-strzyk. 63 mcg + 1 amp.-strzyk. 94 mcg\n00646520437201 ¦ Rpz ¦ EU/1/14/934/002 ¦ 104006\n1 wstrzyk. 63 mcg + 1 wstrzyk. 94 mcg",
  "substance": "Peginterferonum beta-1a 63 mcg/0.5 ml + Peginterferonum beta-1a 94 mcg/0.5 ml",
  "common_name": "Peginterferonum beta-1a",
  "pl_product_id": "100325822",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about peginterferon beta-1a.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console